CAPTURE Screening Tool Has High Specificity for Identifying COPD

TUESDAY, Feb. 14, 2023 (HealthDay News) -- The chronic obstructive pulmonary disease (COPD) Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) screening tool has low sensitivity and high specificity for identifying clinically significant COPD, according to a study published in the Feb. 14 issue of the Journal of the American Medical Association.
Fernando J. Martinez, M.D., from Weill Cornell Medicine/NY Presbyterian Hospital in New York City, and colleagues enrolled 4,325 primary care patients aged 45 to 80 years without a prior COPD diagnosis between Oct. 12, 2018, and April 1, 2022. The CAPTURE tool's sensitivity and specificity for identifying patients with undiagnosed, clinically significant COPD was assessed.
The researchers found that 53 of the 110 patients (2.5 percent) with undiagnosed, clinically significant COPD had a positive screening result, with sensitivity and specificity of 48.2 and 88.6 percent, respectively. For varying positive screening thresholds, the area under the receiver operating characteristic curve was 0.81.
"Further research is needed to optimize performance of the screening tool and to understand whether its use affects clinical outcomes," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including several that funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Sacrospinous Hysteropexy Inferior to Manchester Procedure for Uterine Descent
WEDNESDAY, Aug. 23, 2023 (HealthDay News) -- For patients with uterine descent,...
Health Highlights: Jan. 26, 2023
Autism diagnosis is getting better, but not for everyone. Autism cases are...
Sarah Ferguson Reveals Breast Cancer Diagnosis, Mastectomy
MONDAY, June 26, 2023 (HealthDay News) -- Sarah Ferguson has undergone treatment...
Health Highlights: April 15, 2022
FDA approves first breath test for COVID: The results are delivered within three...